Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Stem cell-derived islet therapy: is this the end of the beginning?

Nature Reviews Endocrinology volume 19, pages 681–682 (2023)Cite this article

Subjects

The debut of stem cell-derived islets in the clinic for glycaemic control in patients with type 1 diabetes mellitus has garnered much excitement. Ongoing research in this field guarantees to be transformative for modern treatment of diabetes mellitus.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: ‘Smart’ SC-islets.

References

  1. Banting, F. G. Nobel lecture: diabetes and insulin. The Nobel Prize https://www.nobelprize.org/prizes/medicine/1923/banting/lecture/ (1925).

  2. Balboa, D. et al. Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells. Nat. Biotechnol. 40, 1042–1055 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Davis, J. C. et al. Glucose response by stem cell-derived β cells in vitro is inhibited by a bottleneck in glycolysis. Cell Rep. 31, 107623 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Augsornworawat, P. et al. Single-nucleus multi-omics of human stem cell-derived islets identifies deficiencies in lineage specification. Nat. Cell Biol. 25, 904–916 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Zhu, H. et al. Understanding cell fate acquisition in stem-cell-derived pancreatic islets using single-cell multiome-inferred regulomes. Dev. Cell 58, 727–743.e11 (2023).

    Article  CAS  PubMed  Google Scholar 

  6. Tahbaz, M. & Yoshihara, E. Immune protection of stem cell-derived islet cell therapy for treating diabetes. Front. Endocrinol. (Lausanne) 12, 716625 (2021).

    Article  PubMed  Google Scholar 

  7. Hu, X. et al. Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice. Sci. Transl. Med. 15, eadg5794 (2023).

    Article  CAS  PubMed  Google Scholar 

  8. Gerace, D. et al. Engineering human stem cell-derived islets to evade immune rejection and promote localized immune tolerance. Cell Rep. Med. 4, 100879 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Nakatsuji, N., Nakajima, F. & Tokunaga, K. HLA-haplotype banking and iPS cells. Nat. Biotechnol. 26, 739–740 (2008).

    Article  CAS  PubMed  Google Scholar 

  10. Shapiro, A. M., Pokrywczynska, M. & Ricordi, C. Clinical pancreatic islet transplantation. Nat. Rev. Endocrinol. 13, 268–277 (2017).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Diabetes and Organoid Technology, Helmholtz Munich, Munich, Germany

    Veronica A. Cochrane & Matthias Hebrok

  2. Center for Organoid System, School of Medicine/MRI, Technical University of Munich, Munich, Germany

    Matthias Hebrok

Authors
  1. Veronica A. Cochrane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias Hebrok
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Hebrok.

Ethics declarations

Competing interests

M.H. holds stocks in Encellin Inc. and Thymmune Therapeutics Inc. M.H. consults for CV Next and holds stock in the latter. M.H. is the co-founder and SAB member of Minutia Inc. and holds stocks and options in the company. V.A.C. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cochrane, V.A., Hebrok, M. Stem cell-derived islet therapy: is this the end of the beginning?. Nat Rev Endocrinol 19, 681–682 (2023). https://doi.org/10.1038/s41574-023-00910-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41574-023-00910-8

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing